Structure Therapeutics Free Cash Flow (FCF) History (GPCR)
Structure Therapeutics reported −$225.8M in free cash flow for fiscal 2025, a decrease of $107.9M from the previous fiscal year.
View full Structure Therapeutics company overviewStructure Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$225.8M | −$107.9M | — | — |
| 2024 | 2024-12-31 | −$117.9M | −$36.3M | — | — |
| 2023 | 2023-12-31 | −$81.7M | −$35.4M | — | — |
| 2022 | 2022-12-31 | −$46.3M | — | — | — |
Structure Therapeutics quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$120.2M | −$65.4M | — | — |
| Q1 2026 | 2026-03-31 | $14.1M | $66.6M | — | — |
| Q4 2025 | 2025-12-31 | −$65.9M | −$29.4M | — | — |
| Q3 2025 | 2025-09-30 | −$52.6M | −$32.2M | — | — |
| Q2 2025 | 2025-06-30 | −$54.8M | −$28.0M | — | — |
| Q1 2025 | 2025-03-31 | −$52.5M | −$18.3M | — | — |
| Q4 2024 | 2024-12-31 | −$36.5M | — | — | — |
| Q3 2024 | 2024-09-30 | −$20.4M | $996,000 | — | — |
| Q2 2024 | 2024-06-30 | −$26.8M | — | — | — |
| Q1 2024 | 2024-03-31 | −$34.2M | — | — | — |
| Q3 2023 | 2023-09-30 | −$21.4M | −$10.8M | — | — |
| Q4 2022 | 2022-12-31 | −$12.1M | — | — | — |
| Q3 2022 | 2022-09-30 | −$10.6M | — | — | — |
| Q2 2022 | 2022-06-30 | −$10.1M | — | — | — |
| Q1 2022 | 2022-03-31 | −$13.6M | — | — | — |
Structure Therapeutics free cash flow growth trends
Structure Therapeutics's latest reported quarter, Q2 2026, generated −$120.2M in free cash flow, a decrease of $65.4M year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Structure Therapeutics source filings ↗Community posts
Structure reports up to 16.2% weight loss in extended obesity study
Structure Therapeutics ($GPCR) reported up to 16.2% average body-weight reduction at 72 weeks in an open-label extension study of aleniglipron, its experimental oral GLP-1 treatment. Participants in the highest-performing group had escalate ...